Wave Health Named a 2024 ASCO® Breakthrough Abstract Award Winner


Recognized by Conquer Cancer®, the ASCO® Foundation, and the 2024 ASCO® Breakthrough Program Committee, Prestigious Award Recognizes Top Scoring Study Abstracts


Yokohama, Japan and El Segundo, California – Treatment Technologies & Insights (TTI), a digital health insights and real-world data company and developer of the #1 rated ePRO app for Oncology, Wave Health, announced today it has been named a 2024 ASCO Breakthrough Abstract Award winner in recognition of their 8-clinic PRO-WAVE1 study conducted in Spain. Additionally, the study abstract, “PRO-WAVE1: Monitoring patient reported outcomes (PROs) in prostate cancer through Wave Health, a novel ePRO health platform,” has been invited for poster presentation at the global ASCO meeting, taking place August 8-10 in Japan.

Given by Conquer Cancer, the ASCO Foundation, along with the 2024 ASCO Breakthrough Conference program committee, the award recognizes valuable research in clinical cancer treatment and technology innovations in cancer care. The award distinguishes the highest-scoring abstracts submitted for their global conference.

In the PRO-WAVE1 study, patients engaged with the Wave Health App over a 13-week period. Patients used the app during treatment to complete a series of validated ePRO questionnaires, as well as a Weekly Symptom Review (WSR) assessing 16 Prostate cancer-specific symptoms, including the severity and/or frequency of each symptom.  A report summary of the patients’ WSR was generated for care team to view in Wave Connect, a web-based platform – specifically for care team members to conduct weekly check-ins on patients, including verifying patient completion, evaluating report content, indicating plans for follow up with each patient, and rating their perceived value of the platform.

In addition to a rare high 93% patient compliance rate over the course of the study, 98% of the participating HCPs indicated the Wave Health Platform was “useful” as part of patient care and treatment. Additionally, after completing the study, 78% of the participating patients also responded to an “optional” feedback survey regarding their experience using Wave Health during treatment. Those patients conveyed remarkable experiences, including: 90% reporting being satisfied with the app to track their activities and keep their medical team informed; and 95% describing the information provided by Wave Health as “useful.”

Moreover, profile information collected as part of the study revealed a significant portion of study participants were aged 70 years or older (48%), with a maximum educational background of high school or below (52%), and during the screening process, roughly three in 10 participants (29%) reported low confidence in their ability to use app technologies.

TTI CEO Matt Lashey said, “We are honored to be included in such prestigious company in recognition of innovation to improve cancer care. The benefits of ePROs are well established, but they are not easy to operationalize. To ensure compliance, ePRO solutions must be user-friendly and provide value – to both patients and care teams. Wave Health does exactly that.”


Hospital participants in the PRO-WAVE1 study included: Hospital Universitario Marques de Valdecilla; Complejo Hospitalario de Navarra; Oncológico de Donostia; Fundació Puigvert Barcelona; Hospital Universitario La Paz; Hospital Universitario Virgen del Rocío; Hospital de la Sta. Creu i Sant Pau; and Hospital Universitarios Cruces.

The full study abstract (#192/Poster board #K10) is available here.


ASCO® Breakthrough Conference

Endorsed by the Japan Ministry of Health, Labor and Welfare, the ASCO Breakthrough Conference is offered in collaboration with co-host societies and regional collaborators, to connect practicing clinicians, oncology thought leaders, med-tech pioneers, and research trailblazers to spark new conversations and partnerships that transcend disciplines and nations. For more information about the award, please visit Conquer Cancer, and for more information about the conference: https://conferences.asco.org/breakthrough/program.

Wave Health

Wave Health is comprised of a leading patient app, analytics engine, and HCP Portal that takes in a diverse and unique data set to supplement clinical data with critical context and generates actionable insights to improve health and reduce costs.

Born from a personal cancer experience, TTI built the Wave Health Platform to transform the management and understanding of chronic conditions – outside clinical settings, and is now being used by large pharma, ACOs, and government health agencies around the world to support decentralized clinical trials (DCTs), active oncology surveillance programs, enhance patient engagement, and improve adherence. For more information, please visit www.wavehealth.app.

Next
Next

Novel Study to Assess Wave Health for Stem Cell Transplant Patients Delivers Promising Results and Valuable Real-World Data